A number of different intralesional immunotherapies have been studied in the treatment of metastatic melanoma, such as interleukin-2 (IL2), Bacillus Calmette-Guerin (BCG), checkpoint inhibitors, and oncolytic viruses (11), all to variable degrees of success. The gene discussed is IL2; the disease is metastatic melanoma.